Idorsia presents at the 41st J.P. Morgan Healthcare Conference – Achievements in 2022 provide the foundation for our success in 2023
January 09, 2023 01:00 ET | Idorsia Pharmaceuticals Ltd
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – January 9, 2023 Idorsia Ltd (SIX: IDIA) today announced that Jean-Paul Clozel, Chief Executive Officer of Idorsia, will present at...
Idorsia presents at the 41st J.P. Morgan Healthcare Conference – Achievements in 2022 provide the foundation for our success in 2023
January 09, 2023 01:00 ET | Idorsia Pharmaceuticals Ltd
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – January 9, 2023 Idorsia Ltd (SIX: IDIA) today announced that Jean-Paul Clozel, Chief Executive Officer of Idorsia, will present at...
Idorsia submits a New Drug Application to the US FDA for aprocitentan for the treatment of patients with difficult-to-control hypertension
December 20, 2022 01:00 ET | Idorsia Pharmaceuticals Ltd
The application includes data from the Phase 3 registration study of patients with resistant hypertension, where aprocitentan demonstrated a sustained blood pressure reduction over 48 weeks and was...
Idorsia submits a New Drug Application to the US FDA for aprocitentan for the treatment of patients with difficult-to-control hypertension
December 20, 2022 01:00 ET | Idorsia Pharmaceuticals Ltd
The application includes data from the Phase 3 registration study of patients with resistant hypertension, where aprocitentan demonstrated a sustained blood pressure reduction over 48 weeks and was...
Idorsia initiates OPUS a Phase 3 program to investigate cenerimod for the treatment of patients with systemic lupus erythematosus
December 15, 2022 01:00 ET | Idorsia Pharmaceuticals Ltd
Idorsia to host an investor webcast to discuss the Phase 3 program today at 15:00hrs CET Allschwil, Switzerland – December 15, 2022Idorsia Ltd (SIX: IDIA) today announced that the first patient has...
Idorsia initiates OPUS a Phase 3 program to investigate cenerimod for the treatment of patients with systemic lupus erythematosus
December 15, 2022 01:00 ET | Idorsia Pharmaceuticals Ltd
Idorsia to host an investor webcast to discuss the Phase 3 program today at 15:00hrs CET Allschwil, Switzerland – December 15, 2022Idorsia Ltd (SIX: IDIA) today announced that the first patient has...
Long-term safety and tolerability results with daridorexant in patients with insomnia disorder published in CNS Drugs
December 12, 2022 01:00 ET | Idorsia Pharmaceuticals Ltd
Daridorexant, taken every night for up to 12 months, was well-tolerated with no signs of tolerance (loss of effect) or physical dependence, and no evidence of withdrawal or rebound insomnia upon...
Long-term safety and tolerability results with daridorexant in patients with insomnia disorder published in CNS Drugs
December 12, 2022 01:00 ET | Idorsia Pharmaceuticals Ltd
Daridorexant, taken every night for up to 12 months, was well-tolerated with no signs of tolerance (loss of effect) or physical dependence, and no evidence of withdrawal or rebound insomnia upon...
Swissmedic approves QUVIVIQ (daridorexant) – a first-in-class treatment for chronic insomnia disorder to improve both nighttime symptoms and daytime functioning
December 05, 2022 01:00 ET | Idorsia Pharmaceuticals Ltd
QUVIVIQ™ is indicated for the treatment of adult patients with insomnia characterized by symptoms present for at least three months and considerable impact on daytime functioningQUVIVIQ, Switzerland's...
Swissmedic erteilt Zulassung für QUVIVIQ (Daridorexant) – Erstes Medikament seiner Klasse für Behandlungen chronischer Schlaflosigkeit, das sowohl die nächtlichen Symptome als auch die Leistungsfähigkeit am Tag (Tagesaktivität) verbessert
December 05, 2022 01:00 ET | Idorsia Pharmaceuticals Ltd
QUVIVIQ™ wird angewendet zur Behandlung von Erwachsenen mit Schlafstörungen (Insomnie), deren Symptome seit mindestens 3 Monaten anhalten und eine beträchtliche Auswirkung auf die Tagesaktivität...